TRexBio prices $117M IPO Read in browser

Thank you for reading, Test Researcher! basic Subscription UPGRADE

M T W Th Fri 9 October, 2026

Biopharma's balance of power is shifting, and in January, Endpoints journalists will press the people at the center of it on who's rising, who's falling and where the industry may land by the end of the decade. Join us at #JPM27 for exclusive conversations and interviews you won't get anywhere else. Save $200 on your all-access pass with Early Bird, or join us virtually for free.

presented by The Patent Clock Is Al­ready Run­ning. Why De­vel­op­ment Speed Is Al­so a Com­mer­cial Strat­e­gy

news Exclusive: AI startup Chai lands GSK deal, its 6th pharma partner in 9 months TRexBio prices $117M IPO for Tregs as Retension lands $45M Nasdaq debut for hypertension Peer Review Viking commercial chief is out in a hurry; Gilead looks to BeOne exec for China expansion

Oct 13 11:00 am ET Commercial excellence and AI - a ripple, wave or a tsunami sponsored by ZS Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data sponsored by Natera Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 21 11:00 am ET From prediction to decision: Digital twins and predictive modeling in clinical development sponsored by Flatiron Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel Oct 28 10:30 am ET The evolution of MRD: From molecular detection to clinical decisions sponsored by ABBOTT

The entire healthcare ecosystem is more Silicon Valley-ified than ever before. What tech has actually changed? Is biopharma behind? Find out, join us for Health Tech day.

ENDPOINTS PHARMA New PDUFA deal allots money to rehire FDA reviewers, trade groups say Viatris to make $1.65B Pacira acquisition, adding to momentum in pain Long ignored by drugmakers, preeclampsia is now a focus for WHO and biopharma

in case you missed it 1. Argenx's study flop in Sjögren's overshadows a win in celiac disease 2. Roche does fourth China deal since August, teaming with Defand on degraders 3. Zealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacle 4. Endeavor notches major mid-stage trial win, says IPF drug can reverse disease 5.